Welcome to our dedicated page for Mangoceuticals news (Ticker: $MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mangoceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mangoceuticals's position in the market.
MangoRx (NASDAQ: MGRX) reported a 108% revenue growth in Q1 2024, increasing from $100,000 to $214,000 compared to Q1 2023. This growth is driven by strategic advances in customer acquisition, including the launch of a direct-to-clinic sales division. This allows medical professionals to prescribe MangoRx products directly, reducing customer acquisition costs. The company also acquired a global patent portfolio valued at $35 million for $20 million, aiming to launch non-pharmaceutical products starting with clinical trials in Q3 2024. MangoRx continues to expand its men's health and wellness product line, leveraging a unique telemedicine platform for seamless patient experience.
Mangoceuticals, Inc. (NASDAQ: MGRX) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. The company must reach a bid price of $1.00 per share for ten consecutive days to avoid delisting. Additionally, the 2024 Annual Meeting of Stockholders is scheduled for June 17, 2024.